Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Biologic therapy.

Johannes Gutenberg-University, Mainz, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:4City/State/Province:Mainz
Treatments:Biologic therapyHospital:Johannes Gutenberg-University
Drugs:Journal:Link
Date:Aug 2009

Description:

Patients:
This phase 3 study involved 54 previously treated, relapsed or refractory mantle cell lymphoma patients. The median patient age was 68 years and 85% were male.

Treatment:
Patients were treated with the biologic therapy agent temsirolimus, an inhibitor of the mTOR kinase that interferes with cancer cell growth.

Toxicities:
The most severe toxicities were of grade 4 and included grade 3-4 thrombocytopenia, anemia, neutropenia, weakness, and infection.

Results:
The median overall survival was 12.8 months.

Support:
This study was supported by Wyeth Pharmaceuticals, makers of the study drug.

Correspondence: Dr. Georg Hess; email: [email protected]



Back